Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency

Journal of Investigative Dermatology

Volumn 118, Issue 6, 2002, Pages 923-932

  Helmbach, Heike ^a   Kern, Monika A ^a   Rossmann, Evelyn ^a   Renz, Kristina ^a   Kissel, Christine ^a   Gschwendt, Brigitte ^a   Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Caspase; Cytochrome caspase antibodies; Mitochondric

Indexed keywords

CASPASE 9; CISPLATIN; CYTOCHROME C; DNA FRAGMENT; ETOPOSIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0036275357     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.01786.x     Document Type: Article

References (68)

1. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
2. Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide
3. The Hsp 70 and Hsp60 chaperone machines
4. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation
5. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
6. Ifosfamide, carboplatin, and etoposide: A new regime with a broad spectrum of activity
7. The role of NF-kappaB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells
8. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
9. Cytotoxic drugs and the CD95 pathway
10. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system
11. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
12. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma
13. Purification and catalytic properties of human caspase family members
14. HSP27 inhibits cytochrome c-dependent activation of procaspase-9
15. Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39
16. Drug-resistance in human melanoma
17. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines
18. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines
19. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death
20. Apoptosis and drug response
21. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
22. Bcl-2 antisense plus dacarbacine therapy for malignant melanoma
23. Induction of apoptosis by cancer chemotherapy
24. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: Modulation of proto-oncogene expression
25. Etoposide and cisplatin induced apoptosis in activated RAW 264.7 macrophages is attenuated by cAMP-induced gene expression
26. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance
27. Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells
28. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance
29. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
30. Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE
31. Cellular responses to DNA damage in the absence of poly(ADP-ribose)polymerase
32. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
33. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
34. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)
35. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer
36. Protease activation during apoptosis: Death by a thousand cuts?
37. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
38. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways
39. The chaperone function of hsp70 is required for protection against stress-induced apoptosis
40. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters
41. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines
42. Identification of genes that mediate sensitivity to cispaltin
43. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex
44. Phase II study of a short course of weekly high-dose cisplatin combined with long-term etoposide in metastatic melanoma
45. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release
46. The central effectors of cell death in the immune system
47. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide
48. Two CD95 (APO-1/Fas) signaling pathways
49. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity
50. P-glycoprotein expression in primary and metastatic malignant melanoma
51. Glutathione and related enzymes in tumor progression and metastases of human melanoma
52. Membrane transport proteins associated with drug resistance expressed in human melanoma
53. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process
54. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8-3 and -6 in osteosarcoma
55. Apoptosis and cancer drug targeting
56. Etoposide-induced apoptosis is not associated with the Fas pathway in acute myeloblastic leukemia cells
57. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis
58. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
59. The MRP family and anticancer drug metabolism
60. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose)polymerase
61. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
62. Over-expression of heat shock proteins in carcinogenic endometrium
63. Glutathione-related mechanisms in cellular resistance to anticancer drugs
64. Resistance to etoposide-induced apoptosis in a Burkitt's lymphoma cell line
65. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
66. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9